Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Articles|October 1, 2006
- Volume 0 0
MYLAN ACQUIRES INDIAN GENERIC DRUG MAKER MATRIX LABS
Advertisement
Mylan Laboratories moved into the international generic pharmaceutical market ina big way by announcing an agreement to acquire India's Matrix Labs. Under theagreement, Mylan will buy a 51.5% stake at Matrix under a complex formula thatcould drive the final cost as high as $736 million. Matrix Labs will remain a publiclytraded company in India and will continue to operate independently of Mylan.
Matrix Labs, one of the 12 companies authorized to supply medicines to formerPresident Bill Clinton's Clinton Foundation, is also one of India's leading suppliers ofraw materials for use by other generic pharmaceutical manufacturers in India.
Articles in this issue
about 20 years ago
Equation for Success: Diabetes Medication, Diet, and Exerciseabout 20 years ago
Rx Product Newsabout 20 years ago
OTC Product Newsabout 20 years ago
can you READ these Rxs?about 20 years ago
Juvenile Anabolic Steroid Abuseabout 20 years ago
Compounding Hotlineabout 20 years ago
RESPy AWARD: A Role Model for Pharmacy Studentsabout 20 years ago
Ouch! Time for Flu Shotsabout 20 years ago
Supreme Court Declines to Review Generic Marketing PactsAdvertisement
Related to this article
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
3
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
4
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
5